扩张型心肌病基因证据的系统评估
国际专家组采用ClinGen基因-疾病临床有效性分类框架,对51个与特发性扩张型心肌病(DCM)相关的基因进行证据分级。12个基因(23%)被列为明确或强证据,7个(14%)为中等证据,其余32个(63%)证据有限、有争议或无关联。临床基因检测 panel 多包含高证据基因,但也常纳入缺乏稳健证据的基因。
要点
- 51个DCM相关基因中仅19个有高证据(12个明确/强,7个中等)。
- 高证据基因仅能解释少数DCM病例,遗传架构仍不完整。
- 临床检测panel应优先使用高证据基因,谨慎解读可变证据基因。
核心结论
- 在51个DCM相关基因中,19个具有高证据(12个明确/强证据,7个中等证据),但仅解释少数病例。
- 临床基因检测panel多包含高证据基因,但也常纳入缺乏稳健人类证据的基因。
- 推荐临床实践使用高证据DCM基因,对可变证据基因的变异解读需谨慎。
研究设计与样本
- 国际专家组对特发性DCM单基因关系证据进行系统评估。
- 采用Clinical Genome Resource半定量基因-疾病临床有效性分类框架并针对DCM遗传学修改。
- 评估了51个人类遗传证据基因及16个临床基因检测panel的基因覆盖情况。
主要发现
- 12个基因(23%)来自8个基因本体,被分类为明确证据(BAG3、DES、FLNC、LMNA、MYH7、PLN、RBM20、SCN5A、TNNC1、TNNT2、TTN)或强证据(DSP)。
- 7个基因(14%;ACTC1、ACTN2、JPH2、NEXN、TNNI3、TPM1、VCL)包括2个额外本体被分类为中等证据,可能随额外证据升级为强或明确。
- 19个高证据基因中,6个对肥厚型心肌病有类似分类,3个对致心律失常性右心室心肌病有类似分类。
- 剩余32个基因(63%)中,25个(49%)证据有限,4个(8%)有争议,2个(4%)无疾病关系,1个(2%)仅有人类模型数据支持。
- 16个评估的临床基因检测panel中,大多数明确证据基因被包含,但panel也包含众多人类证据极少的基因。
关键数值与推荐
- 明确/强证据基因:BAG3、DES、FLNC、LMNA、MYH7、PLN、RBM20、SCN5A、TNNC1、TNNT2、TTN(明确)和DSP(强)。
- 中等证据基因:ACTC1、ACTN2、JPH2、NEXN、TNNI3、TPM1、VCL。
- 证据有限基因25个(49%),争议基因4个(8%),无疾病关系基因2个(4%),仅动物模型支持基因1个(2%)。
临床怎么用
- 临床基因检测应优先选择有明确或强证据的DCM基因。
- 对中等证据基因的变异解读需结合临床背景谨慎判断。
- 对证据有限、有争议或无关联基因的变异,应避免常规用于临床决策。
局限性
- 高证据基因仅解释少数DCM病例,遗传架构仍不完整。
- 证据分级基于当前可用证据,部分中等证据基因可能随新证据升级。
- 临床基因检测panel常包含缺乏稳健证据的基因,可能导致变异解读困难。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Each of the cardiomyopathies, classically categorized as hypertrophic cardiomyopathy, dilated cardiomyopathy (DCM), and arrhythmogenic right ventricular cardiomyopathy, has a signature genetic theme. Hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy are largely understood as genetic diseases of sarcomere or desmosome proteins, respectively. In contrast, >250 genes spanning >10 gene ontologies have been implicated in DCM, representing a complex and diverse genetic architecture. To clarify this, a systematic curation of evidence to establish the relationship of genes with DCM was conducted. METHODS: An international panel with clinical and scientific expertise in DCM genetics evaluated evidence supporting monogenic relationships of genes with idiopathic DCM. The panel used the Clinical Genome Resource semiquantitative gene-disease clinical validity classification framework with modifications for DCM genetics to classify genes into categories on the basis of the strength of currently available evidence. Representation of DCM genes on clinically available genetic testing panels was evaluated. RESULTS: Fifty-one genes with human genetic evidence were curated. Twelve genes (23%) from 8 gene ontologies were classified as having definitive (BAG3, DES, FLNC, LMNA, MYH7, PLN, RBM20, SCN5A, TNNC1, TNNT2, TTN) or strong (DSP) evidence. Seven genes (14%; ACTC1, ACTN2, JPH2, NEXN, TNNI3, TPM1, VCL) including 2 additional ontologies were classified as moderate evidence; these genes are likely to emerge as strong or definitive with additional evidence. Of these 19 genes, 6 were similarly classified for hypertrophic cardiomyopathy and 3 for arrhythmogenic right ventricular cardiomyopathy. Of the remaining 32 genes (63%), 25 (49%) had limited evidence, 4 (8%) were disputed, 2 (4%) had no disease relationship, and 1 (2%) was supported by animal model data only. Of the 16 evaluated clinical genetic testing panels, most definitive genes were included, but panels also included numerous genes with minimal human evidence. CONCLUSIONS: In the curation of 51 genes, 19 had high evidence (12 definitive/strong, 7 moderate). It is notable that these 19 genes explain only a minority of cases, leaving the remainder of DCM genetic architecture incompletely addressed. Clinical genetic testing panels include most high-evidence genes; however, genes lacking robust evidence are also commonly included. We recommend that high-evidence DCM genes be used for clinical practice and that caution be exercised in the interpretation of variants in variable-evidence DCM genes.
引用
- Jordan E, Peterson L, Ai T, et al. Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. Circulation. 2021. PMID: 33947203. doi:10.1161/CIRCULATIONAHA.120.053033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。